Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
18 avr. 2023 09h00 HE
|
Immuneering Corporation
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
18 avr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated...
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
12 avr. 2023 16h05 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immunocore to present four posters at AACR Annual Meeting 2023
14 mars 2023 16h30 HE
|
Immunocore Holdings Limited
Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing...
Immuneering Announces Participation in March Investor Conferences
28 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immunocore to present at upcoming investor conferences
28 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
15 févr. 2023 03h00 HE
|
Cytovation
Bergen, Norway, 15 February 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces...
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
02 févr. 2023 02h00 HE
|
Anaveon
BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...
Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers
30 janv. 2023 09h15 HE
|
Aesther Healthcare Acquisition Corp.
Results outline novel bispecific antibody approach that generates strong anti-tumor response in malignant melanoma, holding potential to control important pathways in multiple cancer types Ocean...
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
23 nov. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc...